Back to Journals » International Journal of Women's Health » Volume 5

Peripartum cardiomyopathy: a review

Authors Capriola M

Received 18 August 2012

Accepted for publication 10 October 2012

Published 28 December 2012 Volume 2013:5 Pages 1—8

DOI https://doi.org/10.2147/IJWH.S37137

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3



Michael Capriola

Thomasville Medical Center, Department of Emergency Medicine, Thomasville Medical Center, Thomasville, NC, USA

Abstract: Peripartum cardiomyopathy (PPCM) is a form of dilated cardiomyopathy of unclear etiology affecting women without preexisting heart disease during the last month of pregnancy or during the first 5 months postpartum. Its incidence shows marked geographic and ethnic variation, being most common in Africa and among women of African descent. Most women present in the first month postpartum with typical heart failure symptoms such as dyspnea, lower extremity edema, and fatigue. These symptoms are often initially erroneously diagnosed as part of the normal puerperal process. Diagnosis can be aided by the finding of a significantly elevated serum brain natriuretic peptide. The etiology of PPCM is unclear; however, recent research suggests abnormal prolactin metabolism is seminal in its development, and prolactin antagonism with bromocriptine shows promise as a novel treatment for PPCM.

Keywords: pregnancy, pregnancy complications, cardiovascular, cardiomyopathy, dilated

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.